Lobe Sciences Ltd. (CVE:LOBE)

BRIEF

published on 09/10/2025 at 05:55, 4 months 19 days ago

Lobe Sciences Ltd. and Cynaptec Pharmaceuticals to Present New Cluster Headache Therapy

Lobe Sciences Conjugated Psilocin Cynaptec Pharmaceuticals Cluster Headache Patient Conference
PRESS RELEASE

published on 09/10/2025 at 05:50, 4 months 19 days ago

Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025
Lobe Sciences Ltd. to participate in Clusterbusters 20th Annual U.S. Patient Conference to highlight psilocin treatment for cluster headaches and discuss funding success for further research and development

Patient Advocacy Conjugated Psilocin Chronic Cluster Headaches Lobe Sciences Ltd. Clusterbusters Conference
BRIEF

published on 09/09/2025 at 05:55, 4 months 20 days ago

Lobe Sciences Appoints Marco Mastrodonato to Board

Biopharmaceutical Board Appointment Therapeutic Development Lobe Sciences Marco Mastrodonato
PRESS RELEASE

published on 09/09/2025 at 05:50, 4 months 20 days ago

Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors
Lobe Sciences Ltd. appoints Marco Mastrodonato to its Board of Directors, bringing extensive experience in pharmaceutical and biotechnology industries, enhancing global business acumen

Board Of Directors Pharmaceutical Industry Lobe Sciences Ltd. Marco Mastrodonato Biotechnology Industry
BRIEF

published on 08/15/2025 at 05:05, 5 months 14 days ago

Lobe Sciences Concludes Private Placement to Raise CAD $341,425

Private Placement Canadian Market Biopharmaceutical Equity Offering Lobe Sciences
PRESS RELEASE

published on 08/15/2025 at 05:00, 5 months 14 days ago

Lobe Sciences Announces the Closing of the Previously Announced Private Placement
Lobe Sciences completes non-brokered private placement totaling $341,425 CAD. Securities subject to statutory holding period. Developing treatments for rare diseases

Private Placement Biopharmaceutical Therapeutics Rare Diseases Lobe Sciences
BRIEF

published on 07/29/2025 at 06:15, 6 months ago

Lobe Sciences Announces Private Placement for Corporate Funding

Private Placement Biopharmaceutical Investments Corporate Funding Lobe Sciences
BRIEF

published on 07/29/2025 at 06:13, 6 months ago

Lobe Sciences Ltd. Partners with ArcStone for Market Strategy

Investor Relations Strategic Partnership Capital Markets Biopharmaceutical Market Positioning
PRESS RELEASE

published on 07/29/2025 at 06:10, 6 months ago

Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes
Lobe Sciences announces non-brokered private placement offering of common shares for gross proceeds, focusing on therapeutics for rare diseases

Private Placement Biopharmaceutical Therapeutics Rare Diseases Lobe Sciences
PRESS RELEASE

published on 07/29/2025 at 06:08, 6 months ago

Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory
Lobe Sciences partners with ArcStone Securities to enhance capital market strategy, aiming to increase visibility and deliver shareholder value through scientific innovation and strategic collaboration in North American markets

Capital Markets Biopharmaceutical Investment Community Lobe Sciences ArcStone Securities

Published on 01/29/2026 at 18:45, 4 hours 19 minutes ago

Silver Spruce Appoints Vice-President of Exploration
Published on 01/29/2026 at 18:00, 5 hours 4 minutes ago

PPX Mining Announces Grant of Restricted Share Units and Deferred Share Units
Published on 01/29/2026 at 17:00, 6 hours 4 minutes ago

Sparta Reports on Delay in Filing Annual Financial Statements
Published on 01/29/2026 at 14:30, 8 hours 34 minutes ago

Innodata Selected by Palantir to Accelerate Advanced Initiatives in AI-Powered Rodeo Modernization
Published on 01/29/2026 at 14:00, 9 hours 4 minutes ago

Horizon Aircraft Partners with RAMPF to Manufacture the Fuselage for its Aircraft

View all ACCESSWIRE

Published on 01/29/2026 at 21:02, 2 hours 1 minute ago

Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/29/2026 at 21:01, 2 hours 3 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 01/29/2026 at 20:59, 2 hours 4 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Bluefield Solar Income Fund Limited
Published on 01/29/2026 at 20:57, 2 hours 6 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 01/29/2026 at 20:57, 2 hours 6 minutes ago

2CRSi SA: Record first half: >€198m

View all EQS

Published on 01/29/2026 at 18:00, 5 hours 4 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 5 hours 19 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 5 hours 19 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 5 hours 24 minutes ago

ALTEN: Annual revenue 2025
Published on 01/29/2026 at 10:07, 12 hours 56 minutes ago

Deezer confirms demonetization of up to 85% of AI-music streams due to fraud and moves to sell AI-detection tech

View all LES ECHOS COMFI WIRE

News